EMA unveils trial dataTrial transparency has been a hotly debated topic over the last months, but now, the EMA is turning words into action. The agency will allow public access to clinical trial reports, starting now. more ➔
Dilaforette: Going public with a new nameNew name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future. more ➔
Ysios closes €126m BioFundSpanish start-ups, take heed: One of the biggest biotech funds in Southern Europe has just been closed by Ysios Capital. The Spanish venture firm raised €126.4m to be reinvested in European biotech, … more ➔
Merck drops MS collaboration with ApitopeApitope said it has regained global rights to its IL-10-bolstering vaccination ATX-MS-1467 for remitting-relapsing multiple sclerosis from Merck KGaA. A 2009 contract forsaw that Merck will … more ➔
EPO rules threaten biotech industryThe European Patent Office’s decision to speed up examination of patent applications to 12 months without any transition period is set to ruin biotech SMEs financially and may send a blocking signal … more ➔
Roche’s NSLC mAb outperforms chemoRoche is making up lost ground in immuno-oncology. The Swiss company’s PD-L1 directed immunotherapy atezolizumab is more effective in combatting lung cancer than standard chemotherapy. more ➔
Synvina: BASF and Avantium join forcesThe new joint venture Synvina is positioned in the market for drop-in bioplastics with advanced product characteristics. more ➔
CPhI sheds light on future marketsWith about 38,000 attendees and 2,500 exhibitors, CPhI worldwide in Barcelona has broken another record. Personalised 3D printed pills and hypothesis generation using big data were only two trends … more ➔
EC delays bioeconomy strategy reviewThe fate of the bioeconomy in Europe remains undecided. The evaluation of the European Commission’s bioeconomy strategy plus action plan has been delayed. more ➔
Apeiron licences neuroblastoma antibodyAustrian Apeiron Biologics has outlicensed the global marketing rights for its neuroblastoma antibody dinutuximab beta to British Eusa Pharma. more ➔
